Caring Through Loss: A Conversation on Bereavement
In this powerful episode, we’re joined by Dr. Wendy G. Lichtenthal, a leading expert in grief and bereavement care. Dr.…
09/09/2025
Caring Through Loss: A Conversation on Bereavement
In this powerful episode, we’re joined by Dr. Wendy G. Lichtenthal, a leading expert in grief and bereavement care. Dr.…
|
09/05/2025
Advocating for Patients: Letter to the FDA on RP1 Treatment Access
Hundreds of patients, families, and friends have shared their stories with AIM at Melanoma about the urgent need for access…
09/04/2025
Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma
AIM at Melanoma, in collaboration with its Canadian partner, the Save Your Skin Foundation, is pleased to present this informative…
08/26/2025
Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma
For AIM at Melanoma, August is all about getting ready for a busy September and fall. While August/September is Back…
08/26/2025
Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma
Side Effect Central is a series of articles designed to help patients with melanoma and their caregivers understand the side…
|
08/26/2025
Newly Published Trial Data for Melanoma
Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system…
|
08/26/2025
RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a…
|
08/12/2025
Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness
Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of…
|
08/12/2025
AYA Cancer Conversation: Navigating Young Adult Cancer
We’re excited to share the latest episode of the AIM at Melanoma podcast, featuring an inspiring conversation with Abby Singh,…
|
08/11/2025
IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
|
|
Recent Posts
Sep. 09, 2025
Caring Through Loss: A Conversation on Bereavement
Sep. 05, 2025
Advocating for Patients: Letter to the FDA on RP1 Treatment Access
Sep. 04, 2025
Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma
Aug. 26, 2025
Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma
Aug. 26, 2025